Arvind Natarajan

Senior Vice President, Technical Development at Iovance Biotherapeutics

Speaker

Arvind Natarajan, PhD, MBA, is Senior Vice President of Technical Development at Iovance Biotherapeutics. He has 25+ years of Chemistry-Manufacturing-Controls (CMC) experience in cell and gene therapies, biologics, and vaccines. Over the course of his career, Dr. Natarajan has worked on bringing four novel products to the market: Amtagvi^TM, the first autologous T cell therapy for solid tumor indications (melanoma), Kymriah®, the first Chimeric Antigen Receptor T cell (CAR-T) therapy for acute lymphocytic leukemia and diffuse large B cell lymphoma, Keytruda®, the first anti-PD1 biologic approved for multiple solid tumor indications, and Zostavax®, the first approved vaccine for shingles and post-herpetic neuralgia.

Dr. Natarajan is an elected Fellow at the American Institute for Medical and Biological Engineering (AIMBE). He has earned an MBA from Wharton, a PhD in Chemical Engineering from University of Minnesota, an MS in Microbial Engineering from University of Minnesota, and a MSc in Biology and BE in Electronics and Electrical Engineering from Birla Institute of Technology and Science (BITS) Pilani in India.